Autism spectrum disorder (ASD) has been a difficult and often confusing condition with symptoms of communication, behavior, and social interaction. The exact causes of it are still unknown; however, a revolutionary new study claims that the scientists have discovered a key biological mechanism responsible for autism—a finding that could lead to therapeutic innovations.
The Breakthrough Discovery
The team of scientists from the University of California, San Diego, and several other places has established a connection between autism and the derailment of the brain’s synaptic pruning process. Synaptic pruning is a physiological procedure through which the brain gets rid of unnecessary neural connections to be more efficient, especially in early developmental stages.
The journal Molecular Psychiatry heralds a new article which indicates that autism may be caused by the lack of this pruning process, resulting in ‘spaghetti-like’ overgrowth of the synapses. The latter can be the reason for the sensory issues, social problems, and a narrow range of interests and repetitive behaviors frequently seen in ASD.
The Role of the mTOR Pathway
Specifically, the study focused on mTOR, a pathway regulating synaptic pruning. In the brains of people with autism, this pathway is very active and so the brain cannot get rid of unnecessary connections.
One of the co-authors of the paper, Dr. Robert Naviaux, explains: “An overactive mTOR is like a congestion in the brain’s garbage disposal system. The synapses which are supposed to be pruned stay there, resulting in an excessive load of information processing.”
Potential for New Treatments
Such a finding may set the stage for directed therapies in agreement with the obtained results. In case researchers succeed in creating medicines that adjust the mTOR pathway, it will be possible to correct the synaptic pruning, thus providing relief from certain autism symptoms.
A current trend is to use old drugs that have the same target as mTOR activity to produce new drugs. For instance, rapamycin, an immunosuppressant in organ transplantation, is effective in animal tests. Nonetheless, it is highly likely that more investigation is necessary before experiments with humans occur.
A Step Toward Personalized Medicine
It should be noted that the present investigation is just a start, but it still marks a considerable advance in our knowledge of autism’s biological nature. The future remedies may be more effective if they are set for the individual’s specific brain condition rather than following a uniform prescription.
Dr Naviaux points out that autism belongs to the spectrum disorders, and this means that the etiology and symptoms are so varied that no single cause can be identified. Therefore, this result is an important part of the overall picture of autism.
What’s Next?
Subsequent works should shed more light on the role that mTOR dysfunction plays in autism, where genes and environmental factors come into play in this disease. If at the early stages of trials the results are consistent, then clinical trials could start in a couple of years.
Until now, the research indeed renews the optimism in a bright future of the science when it comes to autism, wherein it can unveil the secrets of the disorder and its occurrence among the human race and develop interventions that can change the course of the disorder in families and individuals who are affected.
